title: Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
abstract: It is unclear whether standard clinical doses of risedronate affect osteocyte viability. This study examined osteocyte viability and bone remodeling rate in early postmenopausal women (1-5 years after menopause) who were treated with a standard clinical dose of risedronate (5 mg/day, orally) for 1 year. Paired transiliac bone biopsies were obtained from 19 postmenopausal women at baseline and after 1-year treatment with placebo (n = 8, mean age 52.9 ± 3.4 years) or risedronate 5 mg/day (n = 11, mean age 52.5 ± 3.4 years). In these samples, we measured osteocyte- and bone remodeling-related variables in trabecular bone. In both the placebo and risedronate groups, empty lacunae were significantly decreased after 1-year treatment compared to baseline. There were no significant differences in osteocyte-related variables between placebo and risedronate. Risedronate significantly reduced bone-remodeling indices including mineralizing surface (MS/BS), bone formation rate (BFR/BS), and activation frequency (Ac.f). Risedronate treatment caused significantly lower MS/BS and Ac.f than placebo administration. In conclusion, risedronate 5 mg/day effectively inhibited bone remodeling but did not significantly reduce osteocyte viability in trabecular bone.
authors.affiliation: Bone and Mineral Research Laboratory, Henry Ford Hospital, E&R Building 7071, 2799 W Grand Blvd., Detroit, MI 48202, USA. qiu@bjc.hfh.edu
authors.forename: S
authors.initials: S
authors.lastname: Qiu
authors.forename: R J
authors.initials: RJ
authors.lastname: Phipps
authors.forename: F H
authors.initials: FH
authors.lastname: Ebetino
authors.forename: S
authors.initials: S
authors.lastname: Palnitkar
authors.forename: D
authors.initials: D
authors.lastname: Sudhaker Rao
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007085:Ilium / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008875:Middle Aged; D010011:Osteocytes / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D000068296:Risedronic Acid; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid